세계의 동물용 재생의료 시장 규모, 점유율, 동향 분석 보고서 : 동물별, 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Veterinary Regenerative Medicine Market Summary

The global veterinary regenerative medicine market size was estimated at USD 336.86 million in 2024 and is projected to reach USD 987.85 million by 2033, growing at a CAGR of 12.94% from 2025 to 2033. The market is advancing, driven by the rising prevalence of chronic and degenerative diseases in animals, advancements in stem cell and gene therapy technologies, growing humanization of pets, and the willingness to spend on advanced care.

The increasing incidence of chronic, degenerative, and age-related conditions such as osteoarthritis, hip dysplasia, tendon injuries, and spinal disorders in companion and livestock animals is driving demand for veterinary regenerative medicine.

Osteoarthritis (OA) causes 80% of lameness and joint disease in companion animals, with rising cases due to obesity and longer lifespans. In young dogs, 39.8% show radiographic OA and 23.6% clinical signs, emphasizing the underreported prevalence and the need for early detection to optimize treatment outcomes. Pet owners and veterinarians are seeking advanced treatment options beyond symptom management to address the root cause of disease. Stem cell therapy, platelet-rich plasma (PRP), and tissue engineering techniques offer the potential to restore function, reduce pain, and improve quality of life. As awareness of these benefits spreads among pet owners, adoption accelerates, creating strong growth potential in regenerative veterinary healthcare.

An increasing number of innovations in stem cell isolation, culture, and delivery methods, alongside breakthroughs in gene therapy and biomaterials, is significantly enhancing the efficacy and safety of veterinary regenerative medicine. For instance, the European Commission approved Arti-Cell Forte, the first stem cell-based veterinary product, offering a ready-to-use, long-term solution for equine lameness, developed by Boehringer Ingelheim and GST to address the underlying joint inflammation causes. Improvements in cell viability, targeted delivery, and minimally invasive application techniques are expanding the range of treatable conditions in small and large animals. These advancements also lower costs, making treatments more accessible to a wider population of pet owners. In addition, increasing veterinary clinical trials and peer-reviewed evidence are strengthening veterinarians' confidence in regenerative approaches, leading to higher recommendation rates and fostering long-term market adoption.

Global Veterinary Regenerative Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary regenerative medicine market report based on animal, product, application, end use and region:

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Small Animals
• Large Animals
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Stem Cells
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Orthopedics
• Trauma/Wound Care
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals/Clinics
• Veterinary Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Regenerative Medicine Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic and degenerative diseases in animals
    • 3.2.1.2. Advancements in stem cell and gene therapy technologies
    • 3.2.1.3. Growing humanization of pets and willingness to spend on advanced care
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High treatment costs and limited accessibility
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Veterinary Regenerative Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Technology Trend Analysis
  • 3.3.5. Pricing Analysis
  • 3.3.6. Product Pipeline Analysis
  • 3.3.7. Estimated Animal Population by region, key species, 2024

Chapter 4. Veterinary Regenerative Medicine Market: Animal Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Veterinary Regenerative Medicine Market: Animal Movement Analysis
• 4.3. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Animal, 2021 to 2033 (USD Million)
• 4.4. Small Animals
  • 4.4.1. Small Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Large Animals
  • 4.5.1. Large Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Regenerative Medicine Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Veterinary Regenerative Medicine Market: Product Movement Analysis
• 5.3. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Stem Cells
  • 5.4.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Regenerative Medicine Market: By Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Veterinary Regenerative Medicine Market: By Application Movement Analysis
• 6.3. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.3.1. Orthopedics
    • 6.3.1.1. Orthopedics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Trauma/Wound Care
    • 6.3.2.1. Trauma/Wound Care Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Others
    • 6.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Regenerative Medicine Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Veterinary Regenerative Medicine Market: By End Use Movement Analysis
• 7.3. Veterinary Regenerative Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals & Clinics
    • 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Veterinary Research Institutes
    • 7.3.2.1. Veterinary Research Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Regenerative Medicine Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Veterinary Regenerative Medicine Market Share, By Region, 2024 & 2033 (USD Million)
• 8.3. Regional Outlook
• 8.4. North America
  • 8.4.1. North America Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. U.S. Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Canada Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Mexico Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. UK Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Germany Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. France Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Italy Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Spain Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Denmark Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Sweden Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Norway Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Japan Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. China Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. India Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Australia Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. South Korea Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Thailand Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Brazil Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Argentina Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. South Africa Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Saudi Arabia Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. UAE Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Kuwait Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.6. Qatar
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Qatar Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.7. Oman
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Oman Veterinary Regenerative Medicine Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heat Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Boehringer Ingelheim International GmbH.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Zoetis Services LLC
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Dechra
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Integra LifeSciences
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Vetherapy
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Vetstem, Inc.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Ardent
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Enso Discoveries
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Animal Cell Therapies, Inc.
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Vetbiologics
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Medrego
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Celavet Inc
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Strategy Mapping
  • 9.3.14. Mergers & Acquisitions
  • 9.3.15. Partnerships & Collaborations
  • 9.3.16. Product launch
  • 9.3.17. Others
• 9.4. List of other key players